An E2F1-HOXB9 transcriptional circuit is associated with breast cancer progression

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Zhussupova, Aisulu ^a   Hayashida, Tetsu ^a   Takahashi, Maiko ^a   Miyao, Kazuhiro ^a   Okazaki, Hiroshi ^a   Jinno, Hiromitsu ^a   Kitagawa, Yuko ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PALBOCICLIB; TRANSCRIPTION FACTOR E2F1; E2F1 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; HOXB9 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER TISSUE; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC CORRELATION; HOMEOBOX; HOXB9 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PROMOTER REGION; REGULATORY SEQUENCE; TRANSCRIPTION REGULATION; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; GENETIC TRANSCRIPTION; GENETICS; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; PHYSIOLOGY; TRANSCRIPTION INITIATION;

BINDING SITES; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; E2F1 TRANSCRIPTION FACTOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MCF-7 CELLS; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 84925445705     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105285     Document Type: Article

References (41)

1. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608: 1-22.
2. Greer JM, Puetz J, Thomas KR, Capecchi MR (2000) Maintenance of functional equivalence during paralogous Hox gene evolution. Nature 403: 661-665. (Pubitemid 30104007)
3. Boncinelli E, Simeone A, Acampora D, Mavilio F (1991) HOX gene activation by retinoic acid. Trends Genet 7: 329-334. (Pubitemid 121002137)
4. Faiella A, Zappavigna V, Mavilio F, Boncinelli E (1994) Inhibition of retinoic acid-induced activation of 3' human HOXB genes by antisense oligonucleotides affects sequential activation of genes located upstream in the four HOX clusters. Proc Natl Acad Sci U S A 91: 5335-5339.
5. Flagiello D, Gibaud A, Dutrillaux B, Poupon MF, Malfoy B (1997) Distinct patterns of all-trans retinoic acid dependent expression of HOXB and HOXC homeogenes in human embryonal and small-cell lung carcinoma cell lines. FEBS Lett 415: 263-267. (Pubitemid 27451945)
6. Daftary GS, Taylor HS (2006) Endocrine regulation of HOX genes. Endocr Rev 27: 331-355. (Pubitemid 43848302)
7. Boncinelli E (1997) Homeobox genes and disease. Curr Opin Genet Dev 7: 331-337.
8. Lechner JF, Fugaro JM, Wong Y, Pass HI, Harris CC, et al. (2001) Perspective: cell differentiation theory may advance early detection of and therapy for lung cancer. Radiat Res 155: 235-238.
9. Abe M, Hamada J, Takahashi O, Takahashi Y, Tada M, et al. (2006) Disordered expression of HOX genes in human non-small cell lung cancer. Oncol Rep 15: 797-802.
10. Stavnes HT, Holth A, Don T, Kaern J, Vaksman O, et al. (2013) HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival. Gynecol Oncol 129: 358-363.
11. Wu X, Chen H, Parker B, Rubin E, Zhu T, et al. (2006) HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition. Cancer Res 66: 9527-9534. (Pubitemid 44623651)
12. Rubin E, Wu X, Zhu T, Cheung JC, Chen H, et al. (2007) A role for the HOXB7 homeodomain protein in DNA repair. Cancer Res 67: 1527-1535. (Pubitemid 46383376)
13. Jin K, Kong X, Shah T, Penet MF, Wildes F, et al. (2012) The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proc Natl Acad Sci U S A 109: 2736-2741.
14. Hayashida T, Takahashi F, Chiba N, Brachtel E, Takahashi M, et al. (2010) HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci U S A 107: 1100-1105.
15. Shrestha B, Ansari KI, Bhan A, Kasiri S, Hussain I, et al. (2012) Homeodomain-containing protein HOXB9 regulates expression of growth and angiogenic factors, facilitates tumor growth in vitro and is overexpressed in breast cancer tissue. FEBS J 279: 3715-3726.
16. Seki H, Hayashida T, Jinno H, Hirose S, Sakata M, et al. (2012) HOXB9 expression promoting tumor cell proliferation and angiogenesis is associated with clinical outcomes in breast cancer patients. Ann Surg Oncol 19: 1831-1840.
17. Chiba N, Comaills V, Shiotani B, Takahashi F, Shimada T, et al. (2012) Homeobox B9 induces epithelial-to-mesenchymal transition-associated radioresistance by accelerating DNA damage responses. Proc Natl Acad Sci U S A 109: 2760-2765.
18. Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, et al. (2009) WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138: 51-62.
19. Huang K, Yuan R, Wang K, Hu J, Huang Z, et al. (2014) Overexpression of HOXB9 promotes metastasis and indicates poor prognosis in colon cancer. Chin J Cancer Res 26: 72-80.
20. Hoshino Y, Hayashida T, Hirata A, Takahashi H, Chiba N, et al. (2014) Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication. Molecular Cancer 13.
21. Kwon MJ, Nam ES, Cho SJ, Park HR, Shin HS, et al. (2010) E2F1 expression predicts outcome in Korean women who undergo surgery for breast carcinoma. Ann Surg Oncol 17: 564-571.
22. Alinari L, Prince CJ, Edwards RB, Towns WH, Mani R, et al. (2012) Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol. Clin Cancer Res 18: 4600-4611.
23. Wyllie AH (2002) E2F1 selects tumour cells for both life and death. J Pathol 198: 139-141.
24. Black RA, Azizkhan-Clifford J (1999) Regulation of E2F: a family of transcription factors involved in proliferation control. Gene 237: 281-302.
25. Stevaux O, Dyson NJ (2002) A revised picture of the E2F transcriptional network and RB function. Curr Opin Cell Biol 14: 684-691. (Pubitemid 35449380)
26. Phillips AC Vousden KH (2001) E2F-1 induced apoptosis. Apoptosis 6: 173-182. (Pubitemid 32423726)
27. Gorgoulis VG, Zacharatos P, Mariatos G, Kotsinas A, Bouda M, et al. (2002) Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol 198: 142-156. (Pubitemid 35243872)
28. Oyama T, Osaki T, Baba T, Nagata Y, Mizukami M, et al. (2005) Molecular genetic tumor markers in non-small cell lung cancer. Anticancer Res 25: 1193-1196. (Pubitemid 40546789)
29. Zacharatos P, Kotsinas A, Evangelou K, Karakaidos P, Vassiliou LV, et al. (2004) Distinct expression patterns of the transcription factor E2F-1 in relation to tumour growth parameters in common human carcinomas. J Pathol 203: 744-753. (Pubitemid 38961560)
30. Bramis J, Zacharatos P, Papaconstantinou I, Kotsinas A, Sigala F, et al. (2004) E2F-1 transcription factor immunoexpression is inversely associated with tumor growth in colon adenocarcinomas. Anticancer Res 24: 3041-3047. (Pubitemid 39407184)
31. Ebihara Y, Miyamoto M, Shichinohe T, Kawarada Y, Cho Y, et al. (2004) Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression. Dis Esophagus 17: 150-154. (Pubitemid 39076937)
32. Evangelou K, Kotsinas A, Mariolis-Sapsakos T, Giannopoulos A, Tsantoulis PK, et al. (2008) E2F-1 overexpression correlates with decreased proliferation and better prognosis in adenocarcinomas of Barrett oesophagus. J Clin Pathol 61: 601-605. (Pubitemid 351678211)
33. Lee J, Park CK, Park JO, Lim T, Park YS, et al. (2008) Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. Clin Cancer Res 14: 82-88. (Pubitemid 351409260)
34. Mega S, Miyamoto M, Ebihara Y, Takahashi R, Hase R, et al. (2005) Cyclin D1, E2F1 expression levels are associated with characteristics and prognosis of esophageal squamous cell carcinoma. Dis Esophagus 18: 109-113. (Pubitemid 40975423)
35. Palaiologou M, Koskinas J, Karanikolas M, Fatourou E, Tiniakos DG (2012) E2F-1 is overexpressed and pro-apoptotic in human hepatocellular carcinoma. Virchows Arch 460: 439-446.
36. Yamazaki K, Yajima T, Nagao T, Shinkawa H, Kondo F, et al. (2003) Expression of transcription factor E2F-1 in pancreatic ductal carcinoma: an immunohistochemical study. Pathol Res Pract 199: 23-28. (Pubitemid 36322359)
37. Han SH, Park K, Bae BN, Kim KH, Kim HJ, et al. (2003) E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide. Breast Cancer Research and Treatment 82: 6.
38. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, et al. (2009) PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 11: R77.
39. Ansari KI, Shrestha B, Hussain I, Kasiri S, Mandal SS (2011) Histone methylases MLL1 and MLL3 coordinate with estrogen receptors in estrogen-mediated HOXB9 expression. Biochemistry 50: 3517-3527.
40. Finn RS Crown JP, Lang I, Boer K, Bondarenko IM, et al. (2012) Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (BC). Cancer Research 72: Supplement 3.
41. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, et al. (2004) Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3: 1427-1438.